Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
With Tigit out of favour Belgium’s Iteos reckons it could have the best possible PD-(L)1 combo, but does GSK share its optimism?
Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.
Conventional wisdom says manufacturing takes second place to clinical development, but Point turned that on its head, and now a big catalyst approaches.
Checkpoint Therapeutics’ cosibelimab could become the ninth PD-(L)1 drug to reach the US market, but who will be around to launch it?
The promise of fast timelines and early revenues lure a new investor into digital medicine.
With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.
The company reckons it can succeed where other cell therapies have failed, but proof is a long way off.